AGPAT5

Across TCGA pan-cancer cohorts, AGPAT5 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated AGPAT5 data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher AGPAT5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated AGPAT5 expression acts as an unfavorable survival marker.

STAD, SCLC, and PRAD are the cancer types where AGPAT5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Median	All	0.192	0.555	.025	12	view →
SCLC	OS	Median	All	0.205	0.713	.003	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

AGPAT5–STAD (DFS)

Open the STAD breakdown →